Retrophin Inc Cmn (RTRX) 16.10 $RTRX Retrophin
Post# of 273258
Posted On: 09/03/2016 3:05:44 AM
Retrophin Inc Cmn (RTRX) 16.10 $RTRX
Retrophin Appoints Neil McFarlane Chief Operating Officer
GlobeNewswire - Mon Aug 15, 7:30AM CDT
Retrophin, Inc. (NASDAQ:RTRX) today announced Neil McFarlane has been appointed chief operating officer. In this newly created position, Mr. McFarlane will help guide the Company's daily operations with principal responsibility for commercial operations, business development, patient services, and program management. Mr. McFarlane will report to chief executive officer Stephen Aselage.
RTRX: 16.10 (-0.25)
Retrophin Reports Second Quarter 2016 Financial Results
GlobeNewswire - Thu Aug 04, 3:01PM CDT
Second quarter revenues increased 38 percent year-over-year
RTRX: 16.10 (-0.25)
Gilead's (GILD) HIV Treatment Odefsey Gains Approval in EU
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 9:08AM CDT
Gilead Sciences' (GILD) once-daily single tablet regimen Odefsey gained EU approval for the treatment of HIV-1 infection in certain patients.
JNJ: 119.32 (+0.24), GILD: 76.89 (-0.53), ANIP: 59.86 (-1.56), RTRX: 16.10 (-0.25)
Retrophin (RTRX) RE-024 Positive in Physician-Initiated Study
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 5:54AM CDT
Retrophin (RTRX) announced new data from a physician-initiated study on RE-024 for the treatment of pantothenate kinase-associated neurodegeneration (PKAN).
ANIP: 59.86 (-1.56), PFE: 34.77 (+0.09), RTRX: 16.10 (-0.25), ORPN: 1.68 (unch)
Anavex's Lead Candidate Gets Orphan Drug Status Yet Again
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 5:22PM CDT
Anavex Life Sciences (AVXL) announced that ANAVEX 2-73 has been granted orphan drug status by the FDA for the treatment of infantile spasms.
AVXL: 3.05 (+0.02), ANIP: 59.86 (-1.56), RTRX: 16.10 (-0.25), ACOR: 24.27 (-0.07)
Nymox (NYMX) Stock Up on Positive 7-Year Fexapotide Data
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 7:51AM CDT
Nymox (NYMX) announced positive results from the seven-year, prospective, placebo-controlled, double-blind study on fexapotide (NX-1207).
ANIP: 59.86 (-1.56), PFE: 34.77 (+0.09), RTRX: 16.10 (-0.25), NYMX: 3.62 (+0.08)
Retrophin Announces New Data from Physician-Initiated Treatment with RE-024 at the 20th International Congress of Parkinson's Disease and Movement Disorders
GlobeNewswire - Thu Jun 23, 5:00AM CDT
Retrophin, Inc. (NASDAQ:RTRX) today announced new data from physician-initiated treatment with RE-024, the company's novel investigational replacement therapy for pantothenate kinase-associated neurodegeneration (PKAN), a rare and life-threatening genetic condition characterized by a host of progressively debilitating movement disorders. Key findings suggest RE-024 was safe and well tolerated in two adults with PKAN who experienced clinically meaningful improvements, followed by stabilization of disease progression over 47 weeks of treatment.
RTRX: 16.10 (-0.25)
Prima Reports Favorable Initial Breast Cancer Study Data
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 2:30PM CDT
Prima BioMed Ltd (PBMD) announced initial data from a phase IIb chemo-immunotherapy study on IMP321 for the treatment of metastatic breast cancer.
PBMD: 0.85 (unch), ANIP: 59.86 (-1.56), RTRX: 16.10 (-0.25), CELG: 105.49 (-0.88)
GW Pharma (GWPH) to Develop Epidiolex for Infantile Spasms
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 9:53AM CDT
GW Pharmaceuticals (GWPH) has selected infantile spasms as the fourth target indication for the development of Epidiolex.
GWPH: 82.73 (+0.45), ANIP: 59.86 (-1.56), RTRX: 16.10 (-0.25), BMY: 56.35 (-0.41)
Inovio Stock Up, Zika Vaccine Gets Nod for Phase I Study
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 3:51PM CDT
Inovio Pharmaceuticals (INO) and GeneOne Life Science will begin the first Zika vaccine study in human volunteers; Inovio's stock gains.
INO: 9.08 (-0.06), ANIP: 59.86 (-1.56), XON: 25.33 (+0.04), RTRX: 16.10 (-0.25)
Fate's (FATE) ProTmune Gets Fast Track Status, Stock Up
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 10:46AM CDT
Fate Therapeutics (FATE) announced that the FDA has granted the Fast Track status to its immunotherapy ProTmune.
FATE: 2.38 (-0.07), ANIP: 59.86 (-1.56), RTRX: 16.10 (-0.25), ACOR: 24.27 (-0.07)
Gilead Presents Favorable Preliminary Bictegravir HIV Data
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 10:21AM CDT
Gilead Sciences (GILD) presented encouraging preliminary data from four pre-clinical and phase I studies evaluating bictegravir for the treatment of HIV.
GILD: 76.89 (-0.53), ANIP: 59.86 (-1.56), RTRX: 16.10 (-0.25), BMY: 56.35 (-0.41)
Auris (EARS) Begins Phase III Study for Sudden Deafness
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 9:31AM CDT
Auris Medical (EARS) has started patient enrollment in a second pivotal phase III study (ASSENT) on AM-111 for the treatment of sudden deafness.
EARS: 1.71 (unch), ANIP: 59.86 (-1.56), RTRX: 16.10 (-0.25), BMY: 56.35 (-0.41)
Kura (KURA) Begins Dosing in Phase II Study on Cancer Drug
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 3:18PM CDT
Kura Oncology (KURA) announced the dosing of the first patient in a phase II study on tipifarnib for the treatment of lower risk myelodysplastic syndromes.
JNJ: 119.32 (+0.24), RTRX: 16.10 (-0.25), KURA: 5.91 (-0.04), BMY: 56.35 (-0.41)
7 Biotech Stocks that are Buys Right Now
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 10:00AM CDT
Buy these seven biotech stocks now and see how well the second half of 2016 unfolds for this industry.
MSTX: 0.55 (+0.03), RTRX: 16.10 (-0.25), AVEO: 0.90 (-0.01), SNSS: 0.81 (+0.01), LGND: 106.19 (-0.85), BIND: 0.78 (-0.09), ACOR: 24.27 (-0.07)
Zacks.com featured highlights: Dycom Industries, QVC Group, Retrophin, Facebook and Gener8 Maritime
Zacks Equity Research - Zacks Investment Research - Thu Jun 16, 8:30AM CDT
Zacks.com featured highlights: Dycom Industries, QVC Group, Retrophin, Facebook and Gener8 Maritime
GNRT: 4.94 (+0.03), FB: 126.51 (+0.34), RTRX: 16.10 (-0.25), QVCA: 21.26 (-0.01), DY: 86.20 (+3.01)
5 Profitable Stocks for Enhancing Your Portfolio Returns
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 7:18AM CDT
Among the profitability ratios, we have used net income ratio to determine a company's profitability position.
GNRT: 4.94 (+0.03), FB: 126.51 (+0.34), RTRX: 16.10 (-0.25), QVCA: 21.26 (-0.01), DY: 86.20 (+3.01)
Revance's Lead Candidate Fails in Phase III Crow's Feet Study
Zacks Equity Research - Zacks Investment Research - Tue Jun 14, 10:28AM CDT
Revance Therapeutics' (RVNC) RT001 topical failed to meet the co-primary and other endpoints in a phase III crow's feet study.
PFE: 34.77 (+0.09), RTRX: 16.10 (-0.25), RVNC: 13.85 (-0.19), BMY: 56.35 (-0.41)
Agios Reports Favorable Phase II PK Deficiency Study Data
Zacks Equity Research - Zacks Investment Research - Mon Jun 13, 8:56AM CDT
Agios Pharmaceuticals (AGIO) reported encouraging initial data from an ongoing phase II DRIVE-PK study on pyruvate kinase deficiency candidate AG-348.
PFE: 34.77 (+0.09), RTRX: 16.10 (-0.25), AGIO: 36.35 (-0.39), BMY: 56.35 (-0.41)
Glaxo/J&J Sirukumab Positive in Rheumatoid Arthritis Study
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 10:01AM CDT
GlaxoSmithKline (GSK) and Johnson & Johnson's Janssen Biologics announced encouraging new phase III study data on rheumatoid arthritis candidate, sirukumab.
JNJ: 119.32 (+0.24), RTRX: 16.10 (-0.25), GSK: 44.26 (+1.28), BMY: 56.35 (-0.41)
Retrophin Appoints Neil McFarlane Chief Operating Officer
GlobeNewswire - Mon Aug 15, 7:30AM CDT
Retrophin, Inc. (NASDAQ:RTRX) today announced Neil McFarlane has been appointed chief operating officer. In this newly created position, Mr. McFarlane will help guide the Company's daily operations with principal responsibility for commercial operations, business development, patient services, and program management. Mr. McFarlane will report to chief executive officer Stephen Aselage.
RTRX: 16.10 (-0.25)
Retrophin Reports Second Quarter 2016 Financial Results
GlobeNewswire - Thu Aug 04, 3:01PM CDT
Second quarter revenues increased 38 percent year-over-year
RTRX: 16.10 (-0.25)
Gilead's (GILD) HIV Treatment Odefsey Gains Approval in EU
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 9:08AM CDT
Gilead Sciences' (GILD) once-daily single tablet regimen Odefsey gained EU approval for the treatment of HIV-1 infection in certain patients.
JNJ: 119.32 (+0.24), GILD: 76.89 (-0.53), ANIP: 59.86 (-1.56), RTRX: 16.10 (-0.25)
Retrophin (RTRX) RE-024 Positive in Physician-Initiated Study
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 5:54AM CDT
Retrophin (RTRX) announced new data from a physician-initiated study on RE-024 for the treatment of pantothenate kinase-associated neurodegeneration (PKAN).
ANIP: 59.86 (-1.56), PFE: 34.77 (+0.09), RTRX: 16.10 (-0.25), ORPN: 1.68 (unch)
Anavex's Lead Candidate Gets Orphan Drug Status Yet Again
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 5:22PM CDT
Anavex Life Sciences (AVXL) announced that ANAVEX 2-73 has been granted orphan drug status by the FDA for the treatment of infantile spasms.
AVXL: 3.05 (+0.02), ANIP: 59.86 (-1.56), RTRX: 16.10 (-0.25), ACOR: 24.27 (-0.07)
Nymox (NYMX) Stock Up on Positive 7-Year Fexapotide Data
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 7:51AM CDT
Nymox (NYMX) announced positive results from the seven-year, prospective, placebo-controlled, double-blind study on fexapotide (NX-1207).
ANIP: 59.86 (-1.56), PFE: 34.77 (+0.09), RTRX: 16.10 (-0.25), NYMX: 3.62 (+0.08)
Retrophin Announces New Data from Physician-Initiated Treatment with RE-024 at the 20th International Congress of Parkinson's Disease and Movement Disorders
GlobeNewswire - Thu Jun 23, 5:00AM CDT
Retrophin, Inc. (NASDAQ:RTRX) today announced new data from physician-initiated treatment with RE-024, the company's novel investigational replacement therapy for pantothenate kinase-associated neurodegeneration (PKAN), a rare and life-threatening genetic condition characterized by a host of progressively debilitating movement disorders. Key findings suggest RE-024 was safe and well tolerated in two adults with PKAN who experienced clinically meaningful improvements, followed by stabilization of disease progression over 47 weeks of treatment.
RTRX: 16.10 (-0.25)
Prima Reports Favorable Initial Breast Cancer Study Data
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 2:30PM CDT
Prima BioMed Ltd (PBMD) announced initial data from a phase IIb chemo-immunotherapy study on IMP321 for the treatment of metastatic breast cancer.
PBMD: 0.85 (unch), ANIP: 59.86 (-1.56), RTRX: 16.10 (-0.25), CELG: 105.49 (-0.88)
GW Pharma (GWPH) to Develop Epidiolex for Infantile Spasms
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 9:53AM CDT
GW Pharmaceuticals (GWPH) has selected infantile spasms as the fourth target indication for the development of Epidiolex.
GWPH: 82.73 (+0.45), ANIP: 59.86 (-1.56), RTRX: 16.10 (-0.25), BMY: 56.35 (-0.41)
Inovio Stock Up, Zika Vaccine Gets Nod for Phase I Study
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 3:51PM CDT
Inovio Pharmaceuticals (INO) and GeneOne Life Science will begin the first Zika vaccine study in human volunteers; Inovio's stock gains.
INO: 9.08 (-0.06), ANIP: 59.86 (-1.56), XON: 25.33 (+0.04), RTRX: 16.10 (-0.25)
Fate's (FATE) ProTmune Gets Fast Track Status, Stock Up
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 10:46AM CDT
Fate Therapeutics (FATE) announced that the FDA has granted the Fast Track status to its immunotherapy ProTmune.
FATE: 2.38 (-0.07), ANIP: 59.86 (-1.56), RTRX: 16.10 (-0.25), ACOR: 24.27 (-0.07)
Gilead Presents Favorable Preliminary Bictegravir HIV Data
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 10:21AM CDT
Gilead Sciences (GILD) presented encouraging preliminary data from four pre-clinical and phase I studies evaluating bictegravir for the treatment of HIV.
GILD: 76.89 (-0.53), ANIP: 59.86 (-1.56), RTRX: 16.10 (-0.25), BMY: 56.35 (-0.41)
Auris (EARS) Begins Phase III Study for Sudden Deafness
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 9:31AM CDT
Auris Medical (EARS) has started patient enrollment in a second pivotal phase III study (ASSENT) on AM-111 for the treatment of sudden deafness.
EARS: 1.71 (unch), ANIP: 59.86 (-1.56), RTRX: 16.10 (-0.25), BMY: 56.35 (-0.41)
Kura (KURA) Begins Dosing in Phase II Study on Cancer Drug
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 3:18PM CDT
Kura Oncology (KURA) announced the dosing of the first patient in a phase II study on tipifarnib for the treatment of lower risk myelodysplastic syndromes.
JNJ: 119.32 (+0.24), RTRX: 16.10 (-0.25), KURA: 5.91 (-0.04), BMY: 56.35 (-0.41)
7 Biotech Stocks that are Buys Right Now
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 10:00AM CDT
Buy these seven biotech stocks now and see how well the second half of 2016 unfolds for this industry.
MSTX: 0.55 (+0.03), RTRX: 16.10 (-0.25), AVEO: 0.90 (-0.01), SNSS: 0.81 (+0.01), LGND: 106.19 (-0.85), BIND: 0.78 (-0.09), ACOR: 24.27 (-0.07)
Zacks.com featured highlights: Dycom Industries, QVC Group, Retrophin, Facebook and Gener8 Maritime
Zacks Equity Research - Zacks Investment Research - Thu Jun 16, 8:30AM CDT
Zacks.com featured highlights: Dycom Industries, QVC Group, Retrophin, Facebook and Gener8 Maritime
GNRT: 4.94 (+0.03), FB: 126.51 (+0.34), RTRX: 16.10 (-0.25), QVCA: 21.26 (-0.01), DY: 86.20 (+3.01)
5 Profitable Stocks for Enhancing Your Portfolio Returns
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 7:18AM CDT
Among the profitability ratios, we have used net income ratio to determine a company's profitability position.
GNRT: 4.94 (+0.03), FB: 126.51 (+0.34), RTRX: 16.10 (-0.25), QVCA: 21.26 (-0.01), DY: 86.20 (+3.01)
Revance's Lead Candidate Fails in Phase III Crow's Feet Study
Zacks Equity Research - Zacks Investment Research - Tue Jun 14, 10:28AM CDT
Revance Therapeutics' (RVNC) RT001 topical failed to meet the co-primary and other endpoints in a phase III crow's feet study.
PFE: 34.77 (+0.09), RTRX: 16.10 (-0.25), RVNC: 13.85 (-0.19), BMY: 56.35 (-0.41)
Agios Reports Favorable Phase II PK Deficiency Study Data
Zacks Equity Research - Zacks Investment Research - Mon Jun 13, 8:56AM CDT
Agios Pharmaceuticals (AGIO) reported encouraging initial data from an ongoing phase II DRIVE-PK study on pyruvate kinase deficiency candidate AG-348.
PFE: 34.77 (+0.09), RTRX: 16.10 (-0.25), AGIO: 36.35 (-0.39), BMY: 56.35 (-0.41)
Glaxo/J&J Sirukumab Positive in Rheumatoid Arthritis Study
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 10:01AM CDT
GlaxoSmithKline (GSK) and Johnson & Johnson's Janssen Biologics announced encouraging new phase III study data on rheumatoid arthritis candidate, sirukumab.
JNJ: 119.32 (+0.24), RTRX: 16.10 (-0.25), GSK: 44.26 (+1.28), BMY: 56.35 (-0.41)
(0)
(0)Scroll down for more posts ▼